Victoria M Pak1,2, Katherine Russell3, Zhenzhen Shi4,5, Qiang Zhang4,5, John Cox3, Karan Uppal4, Tianwei Yu4,6, Vicki Hertzberg3, Ken Liu4, Octavian C Ioachimescu7,8,9, Nancy Collop7, Donald L Bliwise7, Nancy G Kutner5, Ann Rogers3, Sandra B Dunbar3. 1. School of Nursing, Emory University, 1520 Clifton Road, 243, Atlanta, GA, 30322, USA. Victoria.m.pak@emory.edu. 2. Rollins School of Public Health, Emory University, Atlanta, GA, USA. Victoria.m.pak@emory.edu. 3. School of Nursing, Emory University, 1520 Clifton Road, 243, Atlanta, GA, 30322, USA. 4. Rollins School of Public Health, Emory University, Atlanta, GA, USA. 5. Gangarosa Department of Environmental Health, Atlanta, GA, 30322, USA. 6. Shenzhen Research Institute of Big Data, and School of Data Science, The Chinese University of Hong Kong, Shenzhen, 518172, China. 7. School of Medicine, Emory University, Atlanta, GA, USA. 8. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University - School of Medicine, Atlanta, GA, 30322, USA. 9. Sleep Medicine Section, Atlanta VA Healthcare System, Atlanta, GA, 30322, USA.
Abstract
INTRODUCTION: Excessive daytime sleepiness is a debilitating symptom of obstructive sleep apnea (OSA) linked to cardiovascular disease, and metabolomic mechanisms underlying this relationship remain unknown. We examine whether metabolites from inflammatory and oxidative stress-related pathways that were identified in our prior work could be involved in connecting the two phenomena. METHODS: This study included 57 sleepy (Epworth Sleepiness Scale (ESS) ≥ 10) and 37 non-sleepy (ESS < 10) participants newly diagnosed and untreated for OSA that completed an overnight in-lab or at home sleep study who were recruited from the Emory Mechanisms of Sleepiness Symptoms Study (EMOSS). Differences in fasting blood samples of metabolites were explored in participants with sleepiness versus those without and multiple linear regression models were utilized to examine the association between metabolites and mean arterial pressure (MAP). RESULTS: The 24-h MAP was higher in sleepy 92.8 mmHg (8.4) as compared to non-sleepy 88.8 mmHg (8.1) individuals (P = 0.03). Although targeted metabolites were not significantly associated with MAP, when we stratified by sleepiness group, we found that sphinganine is significantly associated with MAP (Estimate = 8.7, SE = 3.7, P = 0.045) in non-sleepy patients when controlling for age, BMI, smoking status, and apnea-hypopnea index (AHI). CONCLUSION: This is the first study to evaluate the relationship of inflammation and oxidative stress related metabolites in sleepy versus non-sleepy participants with newly diagnosed OSA and their association with 24-h MAP. Our study suggests that Sphinganine is associated with 24 hour MAP in the non-sleepy participants with OSA.
INTRODUCTION: Excessive daytime sleepiness is a debilitating symptom of obstructive sleep apnea (OSA) linked to cardiovascular disease, and metabolomic mechanisms underlying this relationship remain unknown. We examine whether metabolites from inflammatory and oxidative stress-related pathways that were identified in our prior work could be involved in connecting the two phenomena. METHODS: This study included 57 sleepy (Epworth Sleepiness Scale (ESS) ≥ 10) and 37 non-sleepy (ESS < 10) participants newly diagnosed and untreated for OSA that completed an overnight in-lab or at home sleep study who were recruited from the Emory Mechanisms of Sleepiness Symptoms Study (EMOSS). Differences in fasting blood samples of metabolites were explored in participants with sleepiness versus those without and multiple linear regression models were utilized to examine the association between metabolites and mean arterial pressure (MAP). RESULTS: The 24-h MAP was higher in sleepy 92.8 mmHg (8.4) as compared to non-sleepy 88.8 mmHg (8.1) individuals (P = 0.03). Although targeted metabolites were not significantly associated with MAP, when we stratified by sleepiness group, we found that sphinganine is significantly associated with MAP (Estimate = 8.7, SE = 3.7, P = 0.045) in non-sleepy patients when controlling for age, BMI, smoking status, and apnea-hypopnea index (AHI). CONCLUSION: This is the first study to evaluate the relationship of inflammation and oxidative stress related metabolites in sleepy versus non-sleepy participants with newly diagnosed OSA and their association with 24-h MAP. Our study suggests that Sphinganine is associated with 24 hour MAP in the non-sleepy participants with OSA.
Authors: V D F de Mello; M Lankinen; U Schwab; M Kolehmainen; S Lehto; T Seppänen-Laakso; M Oresic; L Pulkkinen; M Uusitupa; A T Erkkilä Journal: Diabetologia Date: 2009-08-11 Impact factor: 10.122
Authors: Zhoumou Chen; Timothy M Doyle; Livio Luongo; Tally M Largent-Milnes; Luigino Antonio Giancotti; Grant Kolar; Silvia Squillace; Serena Boccella; John K Walker; Alexander Pendleton; Sarah Spiegel; William L Neumann; Todd W Vanderah; Daniela Salvemini Journal: Proc Natl Acad Sci U S A Date: 2019-05-08 Impact factor: 11.205